News
Latest News
Poster preliminary proof-of-concept studies
Barcelona - 2A Pharma presents poster at the World Vaccine Congress Europe During the World Vaccine Congress Europe, we presented more details about our preliminary proof-of-concept studies and the development of the active vaccine against EpCAM+...
2A Pharma is attending the 23rd World Vaccine Congress Europe
Aalborg – We are thrilled to announce that Preben and Jeanette will attend the 23rd World Vaccine Congress Europe, which will be held in Barcelona from October 11-14. Poster During the congress, Preben and Jeanette will share more details about the...
2A Pharma celebrates its 5th anniversary
On December 12, 2021, it has been five years since 2A Pharma was founded. This is a good time to look back and be proud of what we’ve accomplished. Watch the video to see the highlights of the past 5 years.
- All
- Collaboration
- Events
- Funding & Investments
- Head & Neck Cancer
- HPV
- Media
- Milestones
Jeanette Prangsgaard speaks about clinical trials
On November 4, Jeanette Prangsgaard held a presentation at the ‘Clinical Trials’ even, organised by…
Read More
2A Pharma is attending the 23rd World Vaccine Congress Europe
Aalborg – We are thrilled to announce that Preben and Jeanette will attend the 23rd…
Read More
Poster preliminary proof-of-concept studies
Barcelona – 2A Pharma presents poster at the World Vaccine Congress Europe During the World…
Read More
Article in MedWatch
Article about 2A Pharma in the Danish pharma/biotech media MedWatch (behind paywall): Danish English: https://medwatch.dk/secure/Top_picks_in_english/article11274345.ece…
Read More
2A Pharma receives approval for phase 1 study of 2AP01
2A Pharma has received approval from the UK Medicines and Healthcare products Regulatory Authority and…
Read More
Eurostars funding for therapeutic head and neck cancer vaccine project
We are extremely pleased to announce that 2A Pharma in collaboration with partners from The…
Read More